{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Analysis of T-cell receptor repertoire from TILs will be descriptive looking for presence or absence of oligoclonal T-cell population.","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab.\n\nPembrolizumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacogenomic Study: Correlative studies","id":"OG000","title":"Treatment (Pembrolizumab)"}],"populationDescription":"Exploratory endpoint. Data not collected.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Analysis of T-cell Receptor Repertoire From TILs","type":"OTHER_PRE_SPECIFIED"}